Bulletin of Experimental Biology and Medicine

, Volume 120, Issue 2, pp 774–778 | Cite as

Effect of substance P on neurological status and behavioral responses altered as a result of prolonged brain ischemia in rats with different types of behavior

  • K. Yu. Sarkisova
  • I. A. Kolomeitseva
  • P. Oehme
Pathological Physiology and General Pathology
  • 16 Downloads

Abstract

Substance P administered 30 min after the onset of cerebral ischemia improved the neurological status and prevented postischemic hyperactivity in rats with a passive type of behavior; had no effect on the neurological status of rats with an intermediate type of behavior but reduced their postischemic hyperactivity; aggravated the neurological status of rats with an active type of behavior without exerting a significant effect on their behavioral responses; and averted a rise in the level of depression in rats of all three groups. The results of this study indicate that there is a relationship between the type of behavior, manifestations of cerebral ischemia, and the effects of substance P.

Key Words

cerebral ischemia behavioral responses substance P 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. G. Airapetyants and A. M. Vein,Experimental and Clinical Neuroses [in Russian], Moscow (1982).Google Scholar
  2. 2.
    G. V. Alekseeva,Zh. Nevropatol. Psikhiatr. 79, 998–1001 (1979).PubMedGoogle Scholar
  3. 3.
    S. V. Girman and I. L. Golovina,Zh. Vyssh. Nervn. Deyat.,39, 349–355 (1989).Google Scholar
  4. 4.
    S. P. Lysenkov, V. G. Korpachev, and L. Z. Tel', in:Clinical Picture, Pathogenesis, and Management of Medical Emergencies [in Russian], Novosibirsk (1982), pp. 8–13.Google Scholar
  5. 5.
    N. I. Nezlina,Zh. Vyssh. Nervn. Deyat. 37, 135–142 (1987).Google Scholar
  6. 6.
    K. Yu. Sarkisova, I. V. Gannushkina, M. V. Baranchikova, et al.,Byull. Eksp. Biol. Med.,112, No 10, 355–357 (1991).Google Scholar
  7. 7.
    K. Yu. Sarkisova, L. V. Nozdracheva, and M. A. Kulikov,Zh. Vyssh. Nervn. Deyat.,41, 963–972 (1991).Google Scholar
  8. 8.
    K. Yu. Sarkisova, P. Oehme, N. I. Artyukhina,et al., Byull. Eksp. Biol. Med.,115, No 2, 208–211, (1993).Google Scholar
  9. 9.
    G. N. Chernobaeva and L. D. Luk'yanova, in:Pharmacological Management of Hypoxic States [in Russian], Moscow (1989), pp. 160–164.Google Scholar
  10. 10.
    E. A. Yumatov, in:Emotional Stress. Physiological and Medicosocial Aspects [in Russian], Kharkov (1990), pp. 43–53.Google Scholar
  11. 11.
    T. Koide, T. W. Wieloch, and K. Siesjo Bo,J. Cereb. Blood Flow Metab.,6, 559–565 (1989).Google Scholar
  12. 12.
    P. Oehme, K. Hecht, H.-D. Faulhaber,et al., J. Cardiovasc. Pharmacol.,10, Suppl. 12, S109-S111 (1987).PubMedGoogle Scholar
  13. 13.
    R. D. Porsolt, A. Bertine, N. Blavet,et al., Europ. J. Pharmacol.,57, 201–210 (1979).CrossRefGoogle Scholar
  14. 14.
    M.-L. Smith, G. Bendek, N. Dahlgren,et al., Acta Neurol. Scand.,69, 385–401 (1984).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • K. Yu. Sarkisova
    • 1
  • I. A. Kolomeitseva
    • 1
  • P. Oehme
    • 2
  1. 1.Group for Experimental Pathology and Therapy of Higher Nervous Activity, Institute of Higher Nervous Activity and NeurophysiologyRussian Academy of SciencesMoscow
  2. 2.Institute of Molecular PharmacologyBerlin

Personalised recommendations